To include your compound in the COVID-19 Resource Center, submit it here.

A Passage to optimal CNS vectors

Passage uses James Wilson’s AAV vectors, gene therapies targeting the CNS

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched last month with a $115.5 million series A round led by OrbiMed Advisors.

Passage Bio Inc. co-founder and interim CEO Stephen Squinto told BioCentury that most other companies in

Read the full 633 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers